tetano
Editor, Senior Moderator
Accurate diagnosis of influenza is critical for clinical management, infection control, and public health actions to minimize the burden of disease. Commercially available rapid influenza diagnostic tests (RIDTs) that detect the influenza virus nucleoprotein (NP) antigen are widely used in clinical practice for diagnosing influenza because they are simple to use and provide results within 15 minutes; however, there has not been a recent comprehensive analytical evaluation of available RIDTs using a standard method with a panel of representative seasonal influenza viruses. This report describes an evaluation of 11 Food and Drug Administration (FDA)?cleared RIDTs using 23 recently circulating influenza viruses under identical conditions in a laboratory setting to assess analytical performance. Most RIDTs detected viral antigens in samples with the highest influenza virus concentrations, but detection varied by virus type and subtype at lower concentrations. Clinicians should be aware of the variability of RIDTs when interpreting negative results and should collect test samples using methods that can maximize the concentration of virus antigen in the sample, such as collecting adequate specimens using appropriate methods in the first 24?72 hours after illness onset. The study design described in this report can be used to evaluate the performance of RIDTs available in the United States now and in the future.
As part of a collaboration between CDC, the Biological Advanced Research and Development Authority, and the Medical College of Wisconsin (MCW), CDC provided 16 influenza A and seven influenza B viruses to MCW to evaluate RIDTs commercially available during the 2011?12 influenza season (Table). Stock viruses were representative of viruses circulating in the United States since 2006 and were characterized by their 50% egg infectious dose (EID50/mL, a measure of virus infectivity). In addition, the concentration of influenza virus NP antigen (the antigen detected by RIDTs) was measured as ?g/mL using isotope dilution tandem mass spectrometry (1). EID50/mL values were at least as high as those reported in human clinical specimens (2?4). MCW prepared swab samples or mock nasal wash specimens from several dilutions of each virus in saline. For nine of 11 RIDTs, 50 ?L of virus dilution was applied to swabs provided in the test kit or swabs described in the manufacturer's instructions for use. Two RIDTs (both manufactured by SA Scientific) require use of nasal wash specimens. Therefore, for the SA Scientific tests, 50 ?L from each virus dilution first was added to saline. All samples, either prepared swabs or liquid, were added to RIDTs and incubated, with results interpreted as described in the instructions for use. Three separate tests were performed for each combination of virus and RIDT.
...
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6143a3.htm?s_cid=mm6143a3_e
As part of a collaboration between CDC, the Biological Advanced Research and Development Authority, and the Medical College of Wisconsin (MCW), CDC provided 16 influenza A and seven influenza B viruses to MCW to evaluate RIDTs commercially available during the 2011?12 influenza season (Table). Stock viruses were representative of viruses circulating in the United States since 2006 and were characterized by their 50% egg infectious dose (EID50/mL, a measure of virus infectivity). In addition, the concentration of influenza virus NP antigen (the antigen detected by RIDTs) was measured as ?g/mL using isotope dilution tandem mass spectrometry (1). EID50/mL values were at least as high as those reported in human clinical specimens (2?4). MCW prepared swab samples or mock nasal wash specimens from several dilutions of each virus in saline. For nine of 11 RIDTs, 50 ?L of virus dilution was applied to swabs provided in the test kit or swabs described in the manufacturer's instructions for use. Two RIDTs (both manufactured by SA Scientific) require use of nasal wash specimens. Therefore, for the SA Scientific tests, 50 ?L from each virus dilution first was added to saline. All samples, either prepared swabs or liquid, were added to RIDTs and incubated, with results interpreted as described in the instructions for use. Three separate tests were performed for each combination of virus and RIDT.
...
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6143a3.htm?s_cid=mm6143a3_e